Pegylatedd interferon alfa-2b monotherapy and pegylated interferon alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B


Kaymakoglu S., Oguz D., Gur G., Gurel S., Tankurt E., Ersoz G., ...More

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol.51, no.8, pp.3020-3022, 2007 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 51 Issue: 8
  • Publication Date: 2007
  • Doi Number: 10.1128/aac.00088-07
  • Title of Journal : ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
  • Page Numbers: pp.3020-3022

Abstract

Forty-eight hepatitis B virus (HBV) E antigen-negative chronic hepatitis B patients received pegylated interferon alfa-2b either alone or with lamivudine for 48 weeks and were followed for an additional 24 weeks. At the end of follow-up, virological response rates (HBV DNA levels of < 400 copies/ml) were similar in the monotherapy (24%) and combination therapy (26%) groups.